Testing a New Medication for Advanced Lung Cancer

Plain-English translation of NCT06424067 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether fingolimod, a medication already approved to treat multiple sclerosis, might also help patients with advanced lung cancer whose disease has continued to grow despite previous treatments. Researchers believe this medication may work differently than standard chemotherapy to slow or stop lung cancer growth. The trial will enroll 38 patients to see if the treatment is safe and effective for two types of lung cancer.

Even with recent advances, patients whose lung cancer continues to grow after two or more rounds of standard treatment have very few options left. This trial explores whether the medication might offer a new way to fight advanced lung cancer by using a different mechanism than existing treatments.

Do you qualify?

You likely qualify if…

you have advanced or metastatic lung cancer (either non-small cell or small cell type) that has progressed despite at least two prior lines of systemic therapy
you are 18 years of age or older
you are able to take oral medication by mouth and willing to follow the treatment plan
you have measurable cancer that can be seen on imaging scans
your overall health status allows you to perform light activities (ECOG performance status 0–2)
you have adequate lymphocyte counts (white blood cell subset) at baseline

You likely don't qualify if…

you have had a heart attack, stroke, or severe heart failure in the last 6 months
you have an abnormal heart rhythm condition called long QT syndrome or certain heart conduction problems (unless you have a pacemaker)
you are currently taking medications that significantly interact with fingolimod or that may cause dangerous heart rhythm problems
you have untreated brain metastases (though previously treated and stable brain tumors may be acceptable)
you are pregnant, breastfeeding, or unwilling to use effective contraception during and for 2 months after the study

What participation looks like

If you qualify, you would take fingolimod orally (by mouth) according to a set schedule while researchers monitor your health with regular blood tests, heart function assessments, and imaging scans to measure your cancer. The study is being conducted at a single institution (Medical University of South Carolina), and you would need to be able to visit for appointments and follow the treatment regimen consistently. The trial includes a safety check-in period at the beginning, followed by the main treatment phase where the focus is on whether the medication helps control your cancer and how well you tolerate it.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

United States

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina